The European Medicines Agency (EMA) has classified MaaT033 as an orphan medicine. This was developed by Lyon, a clinical-stage biotechnology firm devoted to enhancing patient survival rates for those fighting cancer, and a pioneer in the advancement of Microbiome Ecosystem TherapiesTM (MET).

This is the third ODD Lyon has received overall, with MaaT013 already having ODD designation in the US and Europe. However, this is the only ODD that has been issued for MaaT033.

“The European Medicines Agency (EMA) has classified MaaT033 as an orphan medicine“

In order to increase survival rates among individuals receiving HSCT and other cellular treatments, MaaT033 is currently being researched as a complimentary therapy option. It attempts to treat a wider patient group in chronic circumstances and guarantee healthy microbiome function.

Chief Operating Officer of MaaT Pharma, Philippe Moyen, said that “the EMA’s decision to grant orphan drug designation to MaaT033, our second clinical-stage asset and first-in-class therapeutics, recognizes the need for new treatment options for patients with liquid tumors and highlights the potential of microbiome-based drugs further strengthening the value of our clinical assets,”

He continued: “We look forward to continuing to collaborate closely with the regulatory agencies to accelerate the development of safe and innovative microbiome therapies.”

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.